Lerma-Sánchez V, Sánchez-Cárdenas M, Rodríguez-Armida M, Nava-Santana CA, del Toro-Cisneros N, Marino-Vazquez LA, Morales-Buenrostro LE

Language: Spanish
References: 13
Page: 238-242
PDF size: 220.91 Kb.

ABSTRACT

Introduction: Due to their compromised immunity, transplant recipients could be expected to have an unfavorable clinical course after SARS-CoV-2 infection. On the other hand, it has been described that the viral load inhaled by each individual, the low socioeconomic level and even the HLA, could be correlated with the degree of severity of the clinical picture. This becomes relevant in the case of people with close contact as members of the same family who share a home. Objective: To compare the clinical evolution and outcomes of a group of kidney transplant recipients and their relatives, after COVID-19 infection. Methods: It is a comparative and retrospective study. Through the review of the electronic file and phone follow-up, clinical information was obtained of the evolution and outcome of couples infected simultaneously by COVID-19 (transplant recipient-close relative). Results: Data from nine pairs were captured. In four cases, the transplant recipient was older than their relative and in five cases the recipient had greater comorbidity. In relation to the severity of the condition, in six cases there were similar clinical evolution between the recipients and their relatives. There was one death in the group of family members, without deaths in the group of transplant recipients. Conclusions: We present a series of comparative cases with COVID-19, where despite greater comorbidity and immunosuppression, no worse prognosis was observed in the kidney transplant group.

REFERENCES

1. Lo MS, Lee GM, Gunawardane N, Burchett SK, Lachenauer CS, Lehmann LE. The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy. Pediatr Transplant. 2013; 17 (2): 133-143.

2. Wolfromm A, Porcher R, Legoff J, Peffault de Latour R, Xhaard A, de Fontbrune FS et al. Viral respiratory infections diagnosed by multiplex PCR after allogeneic hematopoietic stem cell transplantation: long-term incidence and outcome. Biol Blood Marrow Transplant. 2014; 20 (8): 1238-1241.

3. Paulsen GC, Danziger-Isakov L. Respiratory Viral Infections in Solid Organ and Hematopoietic Stem Cell Transplantation. Clin Chest Med. 2017; 38 (4): 707-726.

4. Gandolfini I, Delsante M, Fiaccadori E, Zaza G, Manenti L, Degli AA et al. COVID-19 in kidney transplant recipients. Am J Transplant. 2020; 20 (7).

5. Haidar G, Singh N. Viral infections in solid organ transplant recipients: novel updates and a review of the classics. Curr Opin Infect Dis. 2017; 30 (6): 579-588.

6. Garcia-Silva R, Hernandez-Dono S, Mena L, Granados J. Mexican human leukocyte antigen alleles might predict clinical outcome in sars-cov-2 infected patients. Rev Invest Clin. 2020; 72 (3): 178-179.

7. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395 (10223): 514-523.

8. Leung WK, To KF, Chan PK, Chan HL, Wu AK, Lee N et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003; 125 (4): 1011-1017.

9. Ning L, Liu L, Li W, Liu H, Wang J, Yao Z et al. Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case report. Am J Transplant. 2020; 20 (7): 1864-1868.

10. Nair V, Jandovitz N, Hirsch JS, Nair G, Abate M, Bhaskaran M et al. COVID-19 in kidney transplant recipients. Am J Transplant. 2020; 20 (7).

11. Uematsu J, Sakai-Sugino K, Kihira-Nakanishi S, Yamamoto H, Hirai K, Kawano M et al. Inhibitions of human parainfluenza virus type 2 replication by ribavirin and mycophenolate mofetil are restored by guanosine and S-(4-nitrobenzyl)-6-thioinosine. Drug Discov Ther. 2019; 13 (6): 314-321.

12. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395 (10229): 1033-1034.

13. Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020; 75 (7): 1667-1670.